These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 35330483)

  • 1. Daratumumab in AL Amyloidosis: A Real-Life Experience of the "RTM" (Regional Tuscan Myeloma Network).
    Sammartano V; Antonioli E; Buda G; Ciofini S; Candi V; Pengue L; Del Giudice ML; Attucci I; Bacchiarri F; Occhini U; Pirrotta MT; Perfetto F; Bocchia M; Gozzetti A
    J Pers Med; 2022 Mar; 12(3):. PubMed ID: 35330483
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Daratumumab for relapsed or refractory AL amyloidosis with high plasma cell burden.
    Schwotzer R; Manz MG; Pederiva S; Waibel C; Caspar C; Lerch E; Flammer AJ; Brouwers S; Seeger H; Heimgartner R; Fehr T; Rossi D; Bianchi E; Stüssi G; Ghilardi G; Gerber B
    Hematol Oncol; 2019 Dec; 37(5):595-600. PubMed ID: 31486522
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Daratumumab in the Treatment of Light-Chain (AL) Amyloidosis.
    Palladini G; Milani P; Malavasi F; Merlini G
    Cells; 2021 Mar; 10(3):. PubMed ID: 33806310
    [TBL] [Abstract][Full Text] [Related]  

  • 4. First-line daratumumab shows high efficacy and tolerability even in advanced AL amyloidosis: the real-world experience.
    Jeryczynski G; Antlanger M; Duca F; Binder-Rodriguez C; Reiter T; Simonitsch-Klupp I; Bonderman D; Kain R; Krauth MT; Agis H
    ESMO Open; 2021 Apr; 6(2):100065. PubMed ID: 33667762
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Daratumumab plus CyBorD for patients with newly diagnosed light chain (AL) amyloidosis.
    Theodorakakou F; Dimopoulos MA; Kastritis E
    Ther Adv Hematol; 2021; 12():20406207211058334. PubMed ID: 34840708
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A prospective phase 2 trial of daratumumab in patients with previously treated systemic light-chain amyloidosis.
    Roussel M; Merlini G; Chevret S; Arnulf B; Stoppa AM; Perrot A; Palladini G; Karlin L; Royer B; Huart A; Macro M; Morel P; Frenzel L; Touzeau C; Boyle E; Dorvaux V; Le Bras F; Lavergne D; Bridoux F; Jaccard A
    Blood; 2020 Apr; 135(18):1531-1540. PubMed ID: 32108228
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Successful Treatment of Systemic Light Chain Amyloidosis with Liver Involvement using Low-Frequency Daratumumab: A Case Report.
    Meng X; He J; Cheng F; Yan H; Zhu C; Guo X; Li Y; Cai Z; He D
    Am J Case Rep; 2024 Jan; 25():e942534. PubMed ID: 38229422
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Daratumumab yields rapid and deep hematologic responses in patients with heavily pretreated AL amyloidosis.
    Kaufman GP; Schrier SL; Lafayette RA; Arai S; Witteles RM; Liedtke M
    Blood; 2017 Aug; 130(7):900-902. PubMed ID: 28615223
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis.
    Kastritis E; Palladini G; Minnema MC; Wechalekar AD; Jaccard A; Lee HC; Sanchorawala V; Gibbs S; Mollee P; Venner CP; Lu J; Schönland S; Gatt ME; Suzuki K; Kim K; Cibeira MT; Beksac M; Libby E; Valent J; Hungria V; Wong SW; Rosenzweig M; Bumma N; Huart A; Dimopoulos MA; Bhutani D; Waxman AJ; Goodman SA; Zonder JA; Lam S; Song K; Hansen T; Manier S; Roeloffzen W; Jamroziak K; Kwok F; Shimazaki C; Kim JS; Crusoe E; Ahmadi T; Tran N; Qin X; Vasey SY; Tromp B; Schecter JM; Weiss BM; Zhuang SH; Vermeulen J; Merlini G; Comenzo RL;
    N Engl J Med; 2021 Jul; 385(1):46-58. PubMed ID: 34192431
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD38 targeted treatment for multiple myeloma.
    Jelínek T; Mihályová J; Hájek R
    Vnitr Lek; 2018; 64(10):939-948. PubMed ID: 30590941
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Daratumumab, pomalidomide, and dexamethasone as a bridging therapy to autologous stem cell transplantation in a case of systemic light-chain amyloidosis with advanced cardiac involvement.
    Arnall JR; Usmani SZ; Adamu H; Mishkin J; Bhutani M
    J Oncol Pharm Pract; 2019 Jun; 25(4):1021-1025. PubMed ID: 30477388
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dual Monoclonal Antibody Therapy in Patients With Systemic AL Amyloidosis and Cardiac Involvement.
    Godara A; Siddiqui NS; Lee LX; Toskic D; Fogaren T; Varga C; Comenzo RL
    Clin Lymphoma Myeloma Leuk; 2020 Mar; 20(3):184-189. PubMed ID: 31983636
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Daratumumab Monotherapy in Severe Patients with AL Amyloidosis and Biopsy-Proven Renal Involvement: A Real Life Experience.
    Roccatello D; Fenoglio R; Naretto C; Baldovino S; Sciascia S; Ferro M; Rossi D
    J Clin Med; 2020 Oct; 9(10):. PubMed ID: 33050272
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Interest of daratumumab in refractory AL amyloidosis in a 96-year-old patient].
    Vial G; Lafargue A; Mercié P; Duffau P; Ribeiro E
    Rev Med Interne; 2022 Nov; 43(11):673-676. PubMed ID: 35934598
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety, tolerability, and response rates of daratumumab in relapsed AL amyloidosis: results of a phase 2 study.
    Sanchorawala V; Sarosiek S; Schulman A; Mistark M; Migre ME; Cruz R; Sloan JM; Brauneis D; Shelton AC
    Blood; 2020 Apr; 135(18):1541-1547. PubMed ID: 31978210
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD38 as Immunotherapeutic Target in Light Chain Amyloidosis and Multiple Myeloma-Association With Molecular Entities, Risk, Survival, and Mechanisms of Upfront Resistance.
    Seckinger A; Hillengass J; Emde M; Beck S; Kimmich C; Dittrich T; Hundemer M; Jauch A; Hegenbart U; Raab MS; Ho AD; Schönland S; Hose D
    Front Immunol; 2018; 9():1676. PubMed ID: 30079070
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Daratumumab for relapsed AL amyloidosis-When cumulative real-world data precedes clinical trials: A multisite study and systematic literature review.
    Shragai T; Gatt M; Lavie N; Vaxman I; Tadmor T; Rouvio O; Zektser M; Horowitz N; Magen H; Ballan M; Suru C; Luttwak E; Levi S; Ziv-Baran T; Avivi I; Cohen YC
    Eur J Haematol; 2021 Feb; 106(2):184-195. PubMed ID: 33090552
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Organ responses with daratumumab therapy in previously treated AL amyloidosis.
    Chung A; Kaufman GP; Sidana S; Eckhert E; Schrier SL; Lafayette RA; Arai S; Witteles RM; Liedtke M
    Blood Adv; 2020 Feb; 4(3):458-466. PubMed ID: 32027745
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment with daratumumab in patients with relapsed/refractory AL amyloidosis: a multicentric retrospective study and review of the literature.
    Lecumberri R; Krsnik I; Askari E; Sirvent M; González-Pérez MS; Escalante F; Pradillo V; Tamariz LE; Cánovas V; Alegre A; Gironella M; González-García ME; Infante MS; Lakhwani S; Martínez-Bilbao C; Dourdil V; Ramírez-Payer Á; Sarrá J; Cibeira MT
    Amyloid; 2020 Sep; 27(3):163-167. PubMed ID: 32106714
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Safety of Daratumumab-based Regimens in Pretreated Light Chain (AL) Amyloidosis: A Systematic Review.
    Ehsan H; Rafae A; Masood A; Wahab A; Sana MK; Ansar I; Neupane K; Umar A; Ehsan A; Hashmi H
    Clin Lymphoma Myeloma Leuk; 2022 May; 22(5):e285-e292. PubMed ID: 34879994
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.